Cargando…
Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA(5m) chelators
BACKGROUND: Fibroblast activation protein (FAP) is a proline selective serine protease that is overexpressed in tumor stroma and in lesions of many other diseases that are characterized by tissue remodeling. In 2014, a most potent FAP-inhibitor (referred to as UAMC1110) with low nanomolar FAP-affini...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7391456/ https://www.ncbi.nlm.nih.gov/pubmed/32728930 http://dx.doi.org/10.1186/s41181-020-00102-z |
_version_ | 1783564640301613056 |
---|---|
author | Moon, Euy Sung Elvas, Filipe Vliegen, Gwendolyn De Lombaerde, Stef Vangestel, Christel De Bruycker, Sven Bracke, An Eppard, Elisabeth Greifenstein, Lukas Klasen, Benedikt Kramer, Vasko Staelens, Steven De Meester, Ingrid Van der Veken, Pieter Rösch, Frank |
author_facet | Moon, Euy Sung Elvas, Filipe Vliegen, Gwendolyn De Lombaerde, Stef Vangestel, Christel De Bruycker, Sven Bracke, An Eppard, Elisabeth Greifenstein, Lukas Klasen, Benedikt Kramer, Vasko Staelens, Steven De Meester, Ingrid Van der Veken, Pieter Rösch, Frank |
author_sort | Moon, Euy Sung |
collection | PubMed |
description | BACKGROUND: Fibroblast activation protein (FAP) is a proline selective serine protease that is overexpressed in tumor stroma and in lesions of many other diseases that are characterized by tissue remodeling. In 2014, a most potent FAP-inhibitor (referred to as UAMC1110) with low nanomolar FAP-affinity and high selectivity toward related enzymes such as prolyl oligopeptidase (PREP) and the dipeptidyl-peptidases (DPPs): DPP4, DPP8/9 and DPP2 were developed. This inhibitor has been adopted recently by other groups to create radiopharmaceuticals by coupling bifunctional chelator-linker systems. Here, we report squaric acid (SA) containing bifunctional DATA(5m) and DOTA chelators based on UAMC1110 as pharmacophor. The novel radiopharmaceuticals DOTA.SA.FAPi and DATA(5m).SA.FAPi with their non-radioactive derivatives were characterized for in vitro inhibitory efficiency to FAP and PREP, respectively and radiochemical investigated with gallium-68. Further, first proof-of-concept in vivo animal study followed by ex vivo biodistribution were determined with [(68)Ga]Ga-DOTA.SA.FAPi. RESULTS: [(68)Ga]Ga-DOTA.SA.FAPi and [(68)Ga]Ga-DATA(5m).SA.FAPi showed high complexation > 97% radiochemical yields after already 10 min and high stability over a period of 2 h. Affinity to FAP of DOTA.SA.FAPi and DATA(5m).SA.FAPi and its (nat)Ga and (nat)Lu-labeled derivatives were excellent resulting in low nanomolar IC(50) values of 0.7–1.4 nM. Additionally, all five compounds showed low affinity for the related protease PREP (high IC(50) with 1.7–8.7 μM). First proof-of-principle in vivo PET-imaging animal studies of the [(68)Ga]Ga-DOTA.SA.FAPi precursor in a HT-29 human colorectal cancer xenograft mouse model indicated promising results with high accumulation in tumor (SUV(mean) of 0.75) and low background signal. Ex vivo biodistribution showed highest uptake in tumor (5.2%ID/g) at 60 min post injection with overall low uptake in healthy tissues. CONCLUSION: In this work, novel PET radiotracers targeting fibroblast activation protein were synthesized and biochemically investigated. Critical substructures of the novel compounds are a squaramide linker unit derived from the basic motif of squaric acid, DOTA and DATA(5m) bifunctional chelators and a FAP-targeting moiety. In conclusion, these new FAP-ligands appear promising, both for further research and development as well as for first human application. |
format | Online Article Text |
id | pubmed-7391456 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-73914562020-08-12 Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA(5m) chelators Moon, Euy Sung Elvas, Filipe Vliegen, Gwendolyn De Lombaerde, Stef Vangestel, Christel De Bruycker, Sven Bracke, An Eppard, Elisabeth Greifenstein, Lukas Klasen, Benedikt Kramer, Vasko Staelens, Steven De Meester, Ingrid Van der Veken, Pieter Rösch, Frank EJNMMI Radiopharm Chem Research Article BACKGROUND: Fibroblast activation protein (FAP) is a proline selective serine protease that is overexpressed in tumor stroma and in lesions of many other diseases that are characterized by tissue remodeling. In 2014, a most potent FAP-inhibitor (referred to as UAMC1110) with low nanomolar FAP-affinity and high selectivity toward related enzymes such as prolyl oligopeptidase (PREP) and the dipeptidyl-peptidases (DPPs): DPP4, DPP8/9 and DPP2 were developed. This inhibitor has been adopted recently by other groups to create radiopharmaceuticals by coupling bifunctional chelator-linker systems. Here, we report squaric acid (SA) containing bifunctional DATA(5m) and DOTA chelators based on UAMC1110 as pharmacophor. The novel radiopharmaceuticals DOTA.SA.FAPi and DATA(5m).SA.FAPi with their non-radioactive derivatives were characterized for in vitro inhibitory efficiency to FAP and PREP, respectively and radiochemical investigated with gallium-68. Further, first proof-of-concept in vivo animal study followed by ex vivo biodistribution were determined with [(68)Ga]Ga-DOTA.SA.FAPi. RESULTS: [(68)Ga]Ga-DOTA.SA.FAPi and [(68)Ga]Ga-DATA(5m).SA.FAPi showed high complexation > 97% radiochemical yields after already 10 min and high stability over a period of 2 h. Affinity to FAP of DOTA.SA.FAPi and DATA(5m).SA.FAPi and its (nat)Ga and (nat)Lu-labeled derivatives were excellent resulting in low nanomolar IC(50) values of 0.7–1.4 nM. Additionally, all five compounds showed low affinity for the related protease PREP (high IC(50) with 1.7–8.7 μM). First proof-of-principle in vivo PET-imaging animal studies of the [(68)Ga]Ga-DOTA.SA.FAPi precursor in a HT-29 human colorectal cancer xenograft mouse model indicated promising results with high accumulation in tumor (SUV(mean) of 0.75) and low background signal. Ex vivo biodistribution showed highest uptake in tumor (5.2%ID/g) at 60 min post injection with overall low uptake in healthy tissues. CONCLUSION: In this work, novel PET radiotracers targeting fibroblast activation protein were synthesized and biochemically investigated. Critical substructures of the novel compounds are a squaramide linker unit derived from the basic motif of squaric acid, DOTA and DATA(5m) bifunctional chelators and a FAP-targeting moiety. In conclusion, these new FAP-ligands appear promising, both for further research and development as well as for first human application. Springer International Publishing 2020-07-29 /pmc/articles/PMC7391456/ /pubmed/32728930 http://dx.doi.org/10.1186/s41181-020-00102-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Moon, Euy Sung Elvas, Filipe Vliegen, Gwendolyn De Lombaerde, Stef Vangestel, Christel De Bruycker, Sven Bracke, An Eppard, Elisabeth Greifenstein, Lukas Klasen, Benedikt Kramer, Vasko Staelens, Steven De Meester, Ingrid Van der Veken, Pieter Rösch, Frank Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA(5m) chelators |
title | Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA(5m) chelators |
title_full | Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA(5m) chelators |
title_fullStr | Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA(5m) chelators |
title_full_unstemmed | Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA(5m) chelators |
title_short | Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA(5m) chelators |
title_sort | targeting fibroblast activation protein (fap): next generation pet radiotracers using squaramide coupled bifunctional dota and data(5m) chelators |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7391456/ https://www.ncbi.nlm.nih.gov/pubmed/32728930 http://dx.doi.org/10.1186/s41181-020-00102-z |
work_keys_str_mv | AT mooneuysung targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators AT elvasfilipe targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators AT vliegengwendolyn targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators AT delombaerdestef targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators AT vangestelchristel targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators AT debruyckersven targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators AT brackean targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators AT eppardelisabeth targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators AT greifensteinlukas targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators AT klasenbenedikt targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators AT kramervasko targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators AT staelenssteven targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators AT demeesteringrid targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators AT vandervekenpieter targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators AT roschfrank targetingfibroblastactivationproteinfapnextgenerationpetradiotracersusingsquaramidecoupledbifunctionaldotaanddata5mchelators |